State Street
BOLT icon

State Street’s Bolt Biotherapeutics BOLT Stock Holding History

State Street’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,372
Closed -$19K – 4269
2025
Q1 		$19K Hold
2,372
– – ﹤0.01% 4210
2024
Q4 		$25.4K Hold
2,372
– – ﹤0.01% 4210
2024
Q3 		$30.7K Hold
2,372
– – ﹤0.01% 4169
2024
Q2 		$35.6K Hold
2,372
– – ﹤0.01% 4205
2024
Q1 		$66.4K Hold
2,372
– – ﹤0.01% 4109
2023
Q4 		$53.1K Sell
2,372
-65
-3% -$1.26K ﹤0.01% 4187
2023
Q3 		$50.7K Hold
2,437
– – ﹤0.01% 4286
2023
Q2 		$62.4K Hold
2,437
– – ﹤0.01% 4361
2023
Q1 		$67.7K Hold
2,437
– – ﹤0.01% 4427
2022
Q4 		$63.4K Hold
2,437
– – ﹤0.01% 4499
2022
Q3 		$72K Hold
2,437
– – ﹤0.01% 4568
2022
Q2 		$99K Sell
2,437
-13,507
-85% -$524K ﹤0.01% 4540
2022
Q1 		$874K Buy
15,944
+284
+2% +$19.1K ﹤0.01% 3849
2021
Q4 		$1.53M Buy
15,660
+1,627
+12% +$309K ﹤0.01% 3718
2021
Q3 		$3.55M Buy
14,033
+3,564
+34% +$1.01M ﹤0.01% 3410
2021
Q2 		$3.24M Buy
10,469
+1,821
+21% +$739K ﹤0.01% 3433
2021
Q1 		$5.69M Buy
+8,648
New +$5.63M ﹤0.01% 3000

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street's BOLT Position: Q2 2025 in Review

State Street sold out of Bolt Biotherapeutics (BOLT) in Q2 2025, closing a stake of 2,372 shares — an estimated $19K sold.

State Street first reported a position in BOLT in Q1 2021 and held it in 17 quarters. The position peaked at $5.69M in Q1 2021. 25 funds tracked by Wall St. Rank hold BOLT as of Q2 2025.

  • State Street reported no remaining Bolt Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • State Street sold 2,372 Bolt Biotherapeutics shares in Q2 2025, an estimated $19K.
  • State Street first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 17 quarters.
  • State Street's Bolt Biotherapeutics position peaked at $5.69M in Q1 2021.
  • 25 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2025.

Based on State Street's 13F filing for Q2 2025, filed 14 Aug 2025.